End-stage renal disease (ESRD) is a significant clinical problem for which dialysis or transplantation is required. The current need for kidneys for transplantation vastly exceeds the supply available from live donors, necessitating the use of kidneys from deceased donors. However, kidneys from deceased donors are associated with reduced viability, as lack of blood supply upon cardiac death increases tissue damage. In addition, the standard protocol for cold preservation of donor kidneys between procurement and transplantation increases the risk of delayed donor kidney function by 23% for every 6-hours of storage. Moreover, compared to other organs, the kidney is particularly prone to transplantation-induced injury due to its high metabolic activities and oxygen consumption. Hence, any minor disturbances in blood supply can easily lead to kidney injury. Therefore, it is not surprising that deceased donor kidneys have a low tolerance for damage associated with lack of blood supply. The focus of the investigators research has been to pioneer the development and supplementation of existing kidney preservation solutions with novel hydrogen sulfide (H2S) donor molecules to improve kidney viability for clinical transplantation. Specifically, the investigators demonstrated that supplementation of standard kidney preservation solutions with non-clinically viable H2S donor molecules significantly increased donor kidney protection and prolonged transplant recipient survival in murine and porcine models of kidney transplantation. Having shown the same salutary effect using sodium thiosulfate (STS; a clinically viable H2S donor drug) in rat kidney transplantation, the investigators aim to repeat this work using STS in porcine and clinical kidney transplantation.

This single-blind study will enroll participants receiving a kidney transplant. Through randomization, half of the participants will receive STS through administration into the pump the kidney is placed on after procurement from the donor and before transplant to the recipient. Participants will be followed for 1-year post transplant where blood and urine will be collected to determine graft function.

The rise in the incidence of end stage renal disease (ESRD) is a global concern. Renal transplantation is the best available treatment for established renal failure, as it not only improves survival, but also improves patient quality of life and is cost effective [1-3]. Unfortunately, there is a widening discrepancy between the incidence of ESRD and the number of available organs for transplantation. While living donor organs have traditionally been preferred, the number of living donors has never been sufficient for all of the patients on the transplant waiting lists. This deficit in organ allocation is expected to rise over the next 20 years due to an increased incidence of ESRD risk factors such as obesity, diabetes and hypertension. This has necessitated increasing the donor pool, with use of organs from extended criteria donors, neurologically deceased donors (NDD), and donation after cardiac death donors (DCD) [4-9].

As expected, maximizing usable organs for transplant with NDD and DCD kidneys comes an increased risk for delayed graft function (DGF) and graft loss. The NDD and DCD kidneys have inherently longer warm ischemic times during the recovery operation, and often have longer cold ischemia times due to the need to transport organs between donor and recipient sites. This results in an increased risk for ischemia-reperfusion injury (IRI). IRI is a complex biological process involving cell death, microcirculatory compromise, altered transcription, inflammation and immune activation [14-16]. While these processes affect all grafts, the effect appears to be greatest in DCD and NDD cohorts. DCD kidneys have up to a 30% risk of graft loss at 5 years and up to 50% in 10 years [10-13].

Significant efforts have been applied to preclinical and clinical settings to develop strategies to ameliorate the negative effects of IRI during organ transplantation. However, there is currently no active pharmacological agent used during transplantation to reduce the impact of IRI. Current strategies include either pulsatile (machine perfusion) or static storage of donor kidneys in various preservation solutions at hypothermic (4ºC) conditions during the peri-transplant period [17]. Hypothermia slows cellular metabolism and subsequent ATP depletion during the ischemic period [18], while organ preservation solutions contain a myriad of electrolytes and other solutes which help to maintain osmotic conditions, scavenge free radicals, and stimulate cellular metabolism upon reperfusion [17]. University of Wisconsin (UW) solution is the most commonly used preservation solution and has been shown to be effective at decreasing the risk of DGF [17].

The addition of a protective pharmacological agent to UW solution may improve graft preservation. Hydrogen sulfide (H2S) has been known for its unsavory "rotten eggs" smell and toxic effects at high concentrations. However, it is also endogenously produced in mammalian cells through the metabolism of L-cysteine and elevated levels are found in hibernating animals. H2S is believed to have a number of cytoprotective effects through anti-inflammatory, anti-oxidative, and anti-apoptotic events. In the kidney, H2S has a direct vasodilatory effect and increased glomerular filtration rate. H2S acts as an endothelium derived relaxing factor that uses Sulphydration mechanisms on vascular smooth muscle cells, interferes with renin production and works synergistically with nitric oxide to upregulate the production of cyclic guanosine monophosphate.

Various H2S donation strategies have been developed and tested in vitro and in vivo. The two most common sources are both sulphide salts, sodium hydrosulfide (NaHS) and sodium sulphide (Na2S) [23]. They dissociate rapidly at physiological pH to generate H2S. However, the resulting bolus of instantly generated H2S does not mimic the endogenous, constitutive enzymatic synthesis of small amounts of H2S. It also has difficulty reaching the mitochondrial target site, which contributes principally to IRI of the renal graft. Other H2S donor compounds such as GYY4137, AP39 and AP123, have offered alternatives but unfortunately are not clinically viable [24,25].

Another possibility is the use of sodium thiosulfate (Na2S2O3, STS), a major metabolite of H2S. It is commercially available as a pentahydrate compound (Na2S2O3·5H2O) and has non-medical uses as a preservative in table salt (less than 0.1%) and alcoholic beverages (less than 0.0005%) [26]. Medically, it is used in the treatment of calciphylaxis in hemodialysis patients [28], cisplatin-induced nephro- and oto-toxicities [29-31], and acute cyanide poisoning [32,33]. It has received Health Canada approval for these applications and short-term use has shown no significant adverse events [34-38]. In addition to its cytoprotective effects, STS also has a vasodilation effect [39,40], which is another important protective property against IRI in organ transplantation.

The study team recently demonstrated the protective effects of STS in a renal transplant rat model. The experiment found that the addition of STS to UW preservation solution resulted in improved graft function and prolonged recipient survival [41]. The protective effect of STS against transplant-induced renal IRI and impact on renal function post-transplantation has not been described in humans. We propose the first randomized controlled trial to evaluate the effects of adding STS to the preservation solution for deceased donor kidneys on graft function and survival.

The purpose of this study is to explore feasibility and efficacy of adding STS to the current preservation solution for deceased donor kidneys to improve renal transplant outcomes. STS is a commercially available H2S donor that is currently used in the treatment of calciphylaxis and cisplatin toxicities in ESRD patients. We have shown that adding STS to the preservation solution in a renal transplant rat model improves graft function and prolonged recipient survival. Although we have experience in transplantation and novel preservation therapies, including treatment with H2S, we need to ensure a feasible and efficient methodology prior to enrolling larger cohorts to assess the effect of STS in a clinical setting. This study will determine the protocol for a future multi-center clinical trial, and provide some preliminary data on the effect of STS enhancement on early graft function.

Primary Objective: To observe the effects of adding STS to the current preservation solution for deceased donor kidneys. Variables being collected for this objective have been split into "primary endpoint variables' for items being collected for all study participants, and 'exploratory variables' for items only being collected if completed as standard of care.

The purpose of this study is to explore feasibility and efficacy of adding STS to the current preservation solution for deceased donor kidneys to improve renal transplant outcomes. STS is a commercially available H2S donor that is currently used in the treatment of calciphylaxis and cisplatin toxicities in ESRD patients. We have shown that adding STS to the preservation solution in a renal transplant rat model improves graft function and prolonged recipient survival. Although we have experience in transplantation and novel preservation therapies, including treatment with H2S, we need to ensure a feasible and efficient methodology prior to enrolling larger cohorts to assess the effect of STS in a clinical setting. This study will determine the protocol for a future multi-center clinical trial, and provide some preliminary data on the effect of STS enhancement on early graft function.

Primary Objective: To observe the effects of adding STS to the current preservation solution for deceased donor kidneys. Variables being collected for this objective have been split into "primary endpoint variables' for items being collected for all study participants, and 'exploratory variables' for items only being collected if completed as standard of care.

This is a single site, randomized, single-blind study. The STS will be added to the preservation fluid in a hypothermic mechanical perfusion kidney transport device. Deceased donor kidney transplant recipients will be randomized 1:1 to either the control (current standard of care) group or the intervention (STS enhancement) group.

For the purposes of this trial, we will store the kidney using a hypothermic mechanical perfusion device for at least two hours, realizing that there will be some variability in the amount of time the kidney is kept in cold solution before being randomized to either the control or STS group. The final data analysis will enable us to separate these variables out further and help design a future, multi-center trial where we will be able to establish strict criteria based on this pilot.

Patient recruitment is expected to be completed over 24 months. Each participant will be followed for 12 months. Data collection will end 12 months after the last participant's transplant. Analysis of the data may take an additional 4 months after the last participant has completed the study.

Inclusion Criteria:

• 18 years of age and over
• End-Stage Renal Disease
• Receiving a kidney transplant from a deceased donor (NDD or DCD)

Exclusion Criteria:

• Under 18 years of age
• Inability to provide informed consent
• Living donor kidney recipients
• Pregnant individuals
• Known allergy to study medication or its components (non-medicinal ingredients)
• Multiorgan transplant patients such as simultaneous kidney pancreas or liver kidney transplants
• Currently enrolled in another interventional transplant clinical trial, or another clinical trial that in the opinion of the QI and PI would greatly impact the results of this study.

Study report

After study completion

To be determined